Age-Related Macular Degeneration Market Size, Epidemiology, Trends, and Forecast 2025-2035

 The age-related macular degeneration market size reached a value of USD 10.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 12.2 Billion by 2035, exhibiting a growth rate (CAGR) of 1.61% during 2025-2035.



Age-related macular degeneration remains one of the leading causes of irreversible blindness among older adults. Advances in imaging and pharmacotherapy have brightened the horizon for these patients, yet the condition continues to impose heavy costs on both victims and health systems. This article surveys the trajectory of incidence, innovation, and market activity as observers peer toward 2025.

Two powerful forces shape that landscape: demographic change and an evolving clinical toolkit.

Worldwide, ophthalmologists now diagnose nearly 2.3 million new cases of AMD each year.

 In the United States alone, surveys suggest that roughly 10% of Americans over fifty harbor the early drusen-laden form, while 1% live with the advanced wet or geographic-atrophy variants.  If demographic projections hold, the pool of affected individuals could swell to around 288 million globally by 2040.

 The financial contours of AMD care reflect this surge through capital and import curves. A recent market study pegged the sector at USD 10.1 billion in 2024, and analysts expect a rise to USD 20.88 billion by 2033, translating into a compound annual-growth rate of about 6.94%. Fueling that expansion are ribbon-thin OCT imaging, gene-edited therapies, and new injectable agents that reassure pay­ers as much as patients. Growing awareness of preventive behavior, from dietary lutein to twice-yearly screening, completes the equation.

Recent Advances in Treatment 

First-line therapies for wet age-related macular degeneration (AMD) continue to evolve. Anti-vascular endothelial growth factor agents-Eylea, Lucentis, and their off-label cousins-temporarily starve abnormal retinal vessels by blocking a key growth signal. A growing number of clinics now alternate or combine these drugs in search of faster stabilization, yet the core mechanism stays unchanged. 

 Away from the injection table, low-level light exposure is earning a following. The LIGHTSITE III trial, conducted in multiple EU nations, reported modest but reproducible gains in visual acuity among patients with intermediate dry AMD. The accomplishment nudged the FDA to issue a breakthrough designation, a rarity for therapies aimed at the more stationary dry form of the disease. 

Diagnostic Innovations 

 Technology is also cutting the delay between symptom onset and clinical confirmation. Handheld OCTs and adaptive optics cameras now share floor space with traditional fundus photography, and their resolution is closing in on single-photoreceptor detail. Home-based devices such as ForeseeHOME have capitalized on this trend by asking patients to complete a brief contrast test every other day. Results upload wirelessly, letting a remote algorithm flag potentially sight-threatening transitions. 

Challenges and Outlook 

 Even rapid progress cannot erase the obstacles embedded in most AMD treatment pathways. Monthly injections remain the gold standard, yet the calendar quickly fills when follow-up imaging and other comorbidities are factored in. Cumulative costs reach five figures for some patients, and that number grows steeper if therapy switches damage non-compliant vessels. Until biosimilars prove widely available or toxicity profiles improve, the balance between promise and persistence will remain delicate.

Analysts expect the age-related macular degeneration sector to keep expanding in the coming years. Trial after trial of gene therapies, along with fresh approaches to drug delivery, hints at safer, less disruptive interventions. Demographers warn that a rapidly graying population will only widen the need for new screening gadgets and therapies, so creative pressure in the field shows no sign of letting up.

Request for a sample of this report: https://www.imarcgroup.com/age-related-macular-degeneration-market/requestsample

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country:

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the age-related macular degeneration market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the age-related macular degeneration market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current age-related macular degeneration marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the age-related macular degeneration market has been studied in the report with the detailed profiles of the key players operating in the market.

1. Novartis AG

2. Genentech USA, Inc.

3. Genentech USA, Inc.

4. Bayer AG

5. Neuraclegenetics

6. OliX Pharmaceuticals, Inc.

7. Ocular Therapeutix, Inc.

8. Sanofi

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=7911&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

Comments

Post a Comment

Popular posts from this blog

Cancer Pain Market Size, Epidemiology, Trends, and Forecast 2025

Image
  The   cancer pain market size   reached a value of USD 1,778.2 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 2,625.8 Million by 2035, exhibiting a growth rate (CAGR) of 3.61% during 2025-2035. The year of 2025 may see the cancer pain market in a raging state, made dynamic from the rise in cancer cases, changing treatment strategies, and significant technological progress. Cancer pain afflicts approximately 53% of all individuals diagnosed with the disease and 64% of those who have the illness at the advanced stage, holding a central position in oncology care. With increasing global cancer incidence, the demand for effective and patient-friendly management of pain has never been higher. A major factor responsible for this expansion is the rising prevalence of cancer worldwide. As the population ages and lifestyle-related risk factors increase, more and more people are getting d...
Read more

Obstructive Sleep Apnea Market Size, Epidemiology, Trends, and Forecast

Image
The 7 major  obstructive sleep apnea markets size  reached a value of USD 794.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 4,066.7 Million by 2035, exhibiting a growth rate (CAGR) of 16.2% during 2025-2035. Increased global awareness, increasing incidence rates, and technological advancements are largely contributing to the growth of the OSA market in 2025. Sleep apnea refers to periodic arousals from sleep accompanied by cessation of breathing and is a common ailment affecting millions of people across the globe. With increasing awareness about associated health risks such as hypertension, cardiovascular diseases, and diabetes, the demand for diagnosis and treatment on time is rapidly increasing.  One of the leading causes of market growth is the increasing incidences of sleep apnea. In the name of modern lifestyles, with instances of poor sleep hygiene, sedentary behavior, and increased calorie intake, sleep apnea cases are surging a...
Read more

Inflammatory Bowel Disease Market Overview and Trends in 2025

Image
 The 7 major  inflammatory bowel disease markets  reached a value of USD 14.92 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 20.08 Billion by 2035, exhibiting a growth rate (CAGR) of 2.73% during 2025-2035. Demand surges in the IBD market as the worldwide burden of chronic gastrointestinal disorders continues to increase in 2025. Crohn’s disease and ulcerative colitis are the two most common types of IBD;  they are lifelong diseases characterized by inflammation of the gastrointestinal tract. Increased awareness of the diseases coupled with the development of diagnostic and therapeutic measures is accelerating market growth globally. The focus areas of the market in 2025 are associated with the growing burden of IBD, particularly in developed North American and European countries. But there is a notable increase in prevalence in portions of Asia and even some Latin American countries, which is likely a result of urban lifestyle, dietary h...
Read more